A Safety and Tolerability Study of QRL-101 in Healthy Participants

The primary objective of this study is to evaluate the safety and tolerability of a novel formulation of QRL-101 in healthy participants. This investigation is clinically relevant to establish the initial safety profile and acceptable dosage parameters for the investigated compound.

The sponsor did not provide information regarding the total number of participants. The study population consists of healthy volunteers, including both male and female individuals. The participants belong to age categories 3 and 4. This population is classified as vulnerable. Reported medical conditions in the source data include epilepsy, amyotrophic lateral sclerosis, and neuropathy.

This Phase 3 clinical trial is designed to evaluate the safety and tolerability of a novel formulation of QRL-101 in healthy participants. The study methodology employs a controlled design to assess the investigational product. The sequence of procedures begins with a screening visit to determine eligibility. Following successful screening, participants proceed through scheduled follow-up visits to monitor clinical responses and safety parameters. The process concludes with an end-of-study visit. The total duration of participation is determined by the specific protocol requirements for each subject. Study termination may occur prematurely if predefined clinical conditions or safety criteria are met.

The assessment of efficacy in this phase 3 clinical trial focuses on evaluating therapeutic responses in subjects with epilepsy, amyotrophic lateral sclerosis, and neuropathy.